Emerging treatments
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma(MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R et al. Lancet Haematol. 2016 Nov 11. pii: S2352-3026(16)30165-X. doi: 10.1016/S2352-3026(16)30165-X. [Epub ahead of print]. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Sanchez L et al. Br J Haematol. 2016…